Cuproptosis-related gene CEP55 as a biomarker of pancreatic adenocarcinoma via multi-omics techniques and experimental validation

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71: 7-33. doi: 10.3322/caac.21654 Siegel RL Miller KD Fuchs HE Jemal A. Cancer Statistics, 2021 . CA Cancer J Clin 2021 ; 71 : 7 - 33 . 10.3322/caac.21654 Open DOISearch in Google Scholar

2. Moore A, Donahue T. Pancreatic cancer. Jama 2019; 322: 1426. doi: 10.1001/jama.2019.14699 Moore A Donahue T. Pancreatic cancer . Jama 2019 ; 322 : 1426 . 10.1001/jama.2019.14699 Open DOISearch in Google Scholar

3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-21. doi: 10.1158/0008-5472.Can-14-0155 Rahib L Smith BD Aizenberg R Rosenzweig AB Fleshman JM Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States . Cancer Res 2014 ; 74 : 2913 - 21 . 10.1158/0008-5472.Can-14-0155 Open DOISearch in Google Scholar

4. Warshaw AL, del Castillo FC. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65. doi: 10.1056/nejm199202133260706 Warshaw AL del Castillo FC. Pancreatic carcinoma . N Engl J Med 1992 ; 326 : 455 - 65 . 10.1056/nejm199202133260706 Open DOISearch in Google Scholar

5. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER cancer statistics review, 1975-2009. [internet]. Bethesda, MD, USA: National Cancer Institute; 2012. [cited 2025 Jan 15]. Available at: http://seer.cancer.gov/csr/1975_2012/ Howlader N Noone AM Krapcho M Garshell J Miller D Altekruse SF SEER cancer statistics review, 1975-2009 . [internet]. Bethesda, MD, USA : National Cancer Institute ; 2012 . [cited 2025 Jan 15 ]. Available at: http://seer.cancer.gov/csr/1975_2012/ Search in Google Scholar

6. Klepsch V, Hermann-Kleiter N, Do-Dinh P, Jakic B, Offermann A, Efremova M, et al. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nat Commun 2018; 9: 1538. doi: 10.1038/s41467-018-04004-2 Klepsch V Hermann-Kleiter N Do-Dinh P Jakic B Offermann A Efremova M Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade . Nat Commun 2018 ; 9 : 1538 . 10.1038/s41467-018-04004-2 Open DOISearch in Google Scholar

7. Li X, Gulati M, Larson AC, Solheim JC, Jain M, Kumar S, et al. Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert. Semin Cancer Biol 2022; 86: 14-27. doi: 10.1016/j.semcancer.2022.08.009 Li X Gulati M Larson AC Solheim JC Jain M Kumar S Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert . Semin Cancer Biol 2022 ; 86 : 14 - 27 . 10.1016/j.semcancer.2022.08.009 Open DOISearch in Google Scholar

8. Heumann T, Azad N. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance. Cancer Metastasis Rev 2021; 40: 837-62. doi: 10.1007/s10555-021-09981-3 Heumann T Azad N. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance . Cancer Metastasis Rev 2021 ; 40 : 837 - 62 . 10.1007/s10555-021-09981-3 Open DOISearch in Google Scholar

9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74. doi: 10.1016/j.cell.2011.02.013 Hanahan D Weinberg RA. Hallmarks of cancer: the next generation . Cell 2011 ; 144 : 646 - 74 . 10.1016/j.cell.2011.02.013 Open DOISearch in Google Scholar

10. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 876-85. doi: 10.1038/nrc1736 Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery . Nat Rev Cancer 2005 ; 5 : 876 - 85 . 10.1038/nrc1736 Open DOISearch in Google Scholar

11. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060-72. doi: 10.1016/j.cell.2012.03.042 Dixon SJ Lemberg KM Lamprecht MR Skouta R Zaitsev EM Gleason CE Ferroptosis: an iron-dependent form of nonapoptotic cell death . Cell 2012 ; 149 : 1060 - 72 . 10.1016/j.cell.2012.03.042 Open DOISearch in Google Scholar

12. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017; 171: 273-85. doi: 10.1016/j.cell.2017.09.021 Stockwell BR Friedmann Angeli JP Bayir H Bush AI Conrad M Dixon SJ Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease . Cell 2017 ; 171 : 273 - 85 . 10.1016/j.cell.2017.09.021 Open DOISearch in Google Scholar

13. Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci 2017; 42: 245-54. doi: 10.1016/j. tibs.2016.10.004 Shi J Gao W Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death . Trends Biochem Sci 2017 ; 42 : 245 - 54 . 10.1016/j. tibs.2016.10.004 Open DOISearch in Google Scholar

14. Fatokun AA, Dawson VL, Dawson TM. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 2014; 171: 2000-16. doi: 10.1111/bph.12416 Fatokun AA Dawson VL Dawson TM. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities . Br J Pharmacol 2014 ; 171 : 2000 - 16 . 10.1111/bph.12416 Open DOISearch in Google Scholar

15. Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 2022; 375: 1254-61. doi: 10.1126/science.abf0529 Tsvetkov P Coy S Petrova B Dreishpoon M Verma A Abdusamad M Copper induces cell death by targeting lipoylated TCA cycle proteins . Science 2022 ; 375 : 1254 - 61 . 10.1126/science.abf0529 Open DOISearch in Google Scholar

16. Li SR, Bu LL, Cai L. Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway. Signal Transduct Target Ther 2022; 7: 158. doi: 10.1038/s41392-022-01014-x Li SR Bu LL Cai L. Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway . Signal Transduct Target Ther 2022 ; 7 : 158 . 10.1038/s41392-022-01014-x Open DOISearch in Google Scholar

17. Sprooten J, De Wijngaert P, Vanmeerbeerk I, Martin S, Vangheluwe P, Schlenner S, et al. Necroptosis in immuno-oncology and cancer immunotherapy. Cells 2020; 9: 1823. doi: 10.3390/cells9081823 Sprooten J De Wijngaert P Vanmeerbeerk I Martin S Vangheluwe P Schlenner S Necroptosis in immuno-oncology and cancer immunotherapy . Cells 2020 ; 9 : 1823 . 10.3390/cells9081823 Open DOISearch in Google Scholar

18. Zhang Z, Zeng X, Wu Y, Liu Y, Zhang X, Song Z. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in hepatocellular carcinoma. Front Immunol 2022; 13: 925618. doi: 10.3389/fimmu.2022.925618 Zhang Z Zeng X Wu Y Liu Y Zhang X Song Z. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in hepatocellular carcinoma . Front Immunol 2022 ; 13 : 925618 . 10.3389/fimmu.2022.925618 Open DOISearch in Google Scholar

19. Li Z, Zhang H, Wang X, Wang Q, Xue J, Shi Y, et al. Identification of cuproptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer. Front Immunol 2022; 13: 996836. doi: 10.3389/fimmu.2022.996836 Li Z Zhang H Wang X Wang Q Xue J Shi Y Identification of cuproptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer . Front Immunol 2022 ; 13 : 996836 . 10.3389/fimmu.2022.996836 Open DOISearch in Google Scholar

20. Ji ZH, Ren WZ, Wang HQ, Gao W, Yuan B. Molecular subtyping based on cuproptosis-related genes and characterization of tumor microenvironment infiltration in kidney renal clear cell carcinoma. Front Oncol 2022; 12: 919083. doi: 10.3389/fonc.2022.919083 Ji ZH Ren WZ Wang HQ Gao W Yuan B. Molecular subtyping based on cuproptosis-related genes and characterization of tumor microenvironment infiltration in kidney renal clear cell carcinoma . Front Oncol 2022 ; 12 : 919083 . 10.3389/fonc.2022.919083 Open DOISearch in Google Scholar

21. Fang Z, Wang W, Liu Y, Hua J, Liang C, Liu J, et al. Cuproptosis-related gene DLAT as a novel biomarker correlated with prognosis, chemoresistance, and immune infiltration in pancreatic adenocarcinoma: a preliminary study based on bioinformatics analysis. Curr Oncol 2023; 30: 2997-3019. doi: 10.3390/curroncol30030228 Fang Z Wang W Liu Y Hua J Liang C Liu J Cuproptosis-related gene DLAT as a novel biomarker correlated with prognosis, chemoresistance, and immune infiltration in pancreatic adenocarcinoma: a preliminary study based on bioinformatics analysis . Curr Oncol 2023 ; 30 : 2997 - 3019 . 10.3390/curroncol30030228 Open DOISearch in Google Scholar

22. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008; 9: 559. doi: 10.1186/14712105-9-559 Langfelder P Horvath S. WGCNA: an R package for weighted correlation network analysis . BMC Bioinformatics 2008 ; 9 : 559 . 10.1186/14712105-9-559 Open DOISearch in Google Scholar

23. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med 1997; 16: 385-95. doi: 10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3 Tibshirani R. The lasso method for variable selection in the Cox model . Stat Med 1997 ; 16 : 385 - 95 . 10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3 Open DOISearch in Google Scholar

24. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17. doi: 10.1056/NEJMra0901557 Hidalgo M. Pancreatic cancer . N Engl J Med 2010 ; 362 : 1605 - 17 . 10.1056/NEJMra0901557 Open DOISearch in Google Scholar

25. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703. doi: 10.1056/NEJMoa1304369 Von Hoff DD Ervin T Arena FP Chiorean EG Infante J Moore M Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine . N Engl J Med 2013 ; 369 : 1691 - 703 . 10.1056/NEJMoa1304369 Open DOISearch in Google Scholar

26. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25. doi: 10.1056/NEJMoa1011923 Conroy T Desseigne F Ychou M Bouché O Guimbaud R Bécouarn Y FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer . N Engl J Med 2011 ; 364 : 1817 - 25 . 10.1056/NEJMoa1011923 Open DOISearch in Google Scholar

27. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432-3. doi: 10.1126/science.342.6165.1432 Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy . Science 2013 ; 342 : 1432 - 3 . 10.1126/science.342.6165.1432 Open DOISearch in Google Scholar

28. Kumar A, Swain CA, Shevde LA. Informing the new developments and future of cancer immunotherapy: future of cancer immunotherapy. Cancer Metastasis Rev 2021; 40: 549-62. doi: 10.1007/s10555-021-09967-1 Kumar A Swain CA Shevde LA. Informing the new developments and future of cancer immunotherapy: future of cancer immunotherapy . Cancer Metastasis Rev 2021 ; 40 : 549 - 62 . 10.1007/s10555-021-09967-1 Open DOISearch in Google Scholar

29. Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 2018; 4: 418-28. doi: 10.1016/j. trecan.2018.04.001 Morrison AH Byrne KT Vonderheide RH. Immunotherapy and prevention of pancreatic cancer . Trends Cancer 2018 ; 4 : 418 - 28 . 10.1016/j. trecan.2018.04.001 Open DOISearch in Google Scholar

30. Yin C, Alqahtani A, Noel MS. The next frontier in pancreatic cancer: targeting the tumor immune milieu and molecular pathways. Cancers 2022; 14: 2619. doi: 10.3390/cancers14112619 Yin C Alqahtani A Noel MS. The next frontier in pancreatic cancer: targeting the tumor immune milieu and molecular pathways . Cancers 2022 ; 14 : 2619 . 10.3390/cancers14112619 Open DOISearch in Google Scholar

31. Li F, He C, Yao H, Liang W, Ye X, Ruan J, et al. GLUT1 regulates the tumor immune microenvironment and promotes tumor metastasis in pancreatic adenocarcinoma via ncRNA-mediated network. J Cancer 2022; 13: 2540-58. doi: 10.7150/jca.72161 Li F He C Yao H Liang W Ye X Ruan J GLUT1 regulates the tumor immune microenvironment and promotes tumor metastasis in pancreatic adenocarcinoma via ncRNA-mediated network . J Cancer 2022 ; 13 : 2540 - 58 . 10.7150/jca.72161 Open DOISearch in Google Scholar

32. Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12: 319-334. doi: 10.1038/nrclinonc.2015.53 Garrido-Laguna I Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies . Nat Rev Clin Oncol 2015 ; 12 : 319 - 334 . 10.1038/nrclinonc.2015.53 Open DOISearch in Google Scholar

33. Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol 2022; 15: 174. doi: 10.1186/s13045-022-01392-3 Tong X Tang R Xiao M Xu J Wang W Zhang B Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research . J Hematol Oncol 2022 ; 15 : 174 . 10.1186/s13045-022-01392-3 Open DOISearch in Google Scholar

34. Qin Y, Liu Y, Xiang X, Long X, Chen Z, Huang X, et al. Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis. Mol Cancer 2023; 22: 59. doi: 10.1186/s12943-023-01752-8 Qin Y Liu Y Xiang X Long X Chen Z Huang X Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis . Mol Cancer 2023 ; 22 : 59 . 10.1186/s12943-023-01752-8 Open DOISearch in Google Scholar

35. Guo B, Yang F, Zhang L, Zhao Q, Wang W, Yin L, et al. Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with αPD-L1 for enhanced cancer immunotherapy. Adv Mater 2023; 35: e2212267. doi: 10.1002/adma.202212267 Guo B Yang F Zhang L Zhao Q Wang W Yin L Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with αPD-L1 for enhanced cancer immunotherapy . Adv Mater 2023 ; 35 : e2212267 . 10.1002/adma.202212267 Open DOISearch in Google Scholar

36. Liu WQ, Lin WR, Yan L, Xu WH, Yang J. Copper homeostasis and cuproptosis in cancer immunity and therapy. Immunol Rev 2024; 321: 211-27. doi: 10.1111/imr.13276 Liu WQ Lin WR Yan L Xu WH Yang J. Copper homeostasis and cuproptosis in cancer immunity and therapy . Immunol Rev 2024 ; 321 : 211 - 27 . 10.1111/imr.13276 Open DOISearch in Google Scholar

37. Li J, Yin J, Li W, Wang H, Ni B. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma. Cancer Cell Int 2023; 23: 7. doi: 10.1186/s12935-022-02836-z Li J Yin J Li W Wang H Ni B. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma . Cancer Cell Int 2023 ; 23 : 7 . 10.1186/s12935-022-02836-z Open DOISearch in Google Scholar

38. Wang G, Chen B, Su Y, Qu N, Zhou D, Zhou W. CEP55 as a promising immune intervention marker to regulate tumor progression: a pan-cancer analysis with experimental verification. Cells 2023; 12: 2457. doi: 10.3390/cells12202457 Wang G Chen B Su Y Qu N Zhou D Zhou W. CEP55 as a promising immune intervention marker to regulate tumor progression: a pan-cancer analysis with experimental verification . Cells 2023 ; 12 : 2457 . 10.3390/cells12202457 Open DOISearch in Google Scholar

39. Neuzillet C, Tijeras-Raballand A, Ragulan C, Cros J, Patil Y, Martinet M, et al. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther 2015; 155: 80-104. doi: 10.1016/j. pharmthera.2015.08.006 Neuzillet C Tijeras-Raballand A Ragulan C Cros J Patil Y Martinet M State of the art and future directions of pancreatic ductal adenocarcinoma therapy . Pharmacol Ther 2015 ; 155 : 80 - 104 . 10.1016/j. pharmthera.2015.08.006 Open DOISearch in Google Scholar

40. Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 2021; 221: 107753. doi: 10.1016/j.pharmthera.2020.107753 Xiao Y Yu D. Tumor microenvironment as a therapeutic target in cancer . Pharmacol Ther 2021 ; 221 : 107753 . 10.1016/j.pharmthera.2020.107753 Open DOISearch in Google Scholar

41. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348: 74-80. doi: 10.1126/science.aaa6204 Joyce JA Fearon DT. T cellexclusion immune privilege and the tumor microenvironment . Science 2015 ; 348 : 74 - 80 . 10.1126/science.aaa6204 Open DOISearch in Google Scholar

42. Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, Lohr JM, et al. Pancreatic cancer microenvironment. Int J Cancer 2007; 121: 699-705. doi: 10.1002/ijc.22871 Kleeff J Beckhove P Esposito I Herzig S Huber PE Lohr JM Pancreatic cancer microenvironment . Int J Cancer 2007 ; 121 : 699 - 705 . 10.1002/ijc.22871 Open DOISearch in Google Scholar

43. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007; 194: S84-86. doi: 10.1016/j.amjsurg.2007.05.004 Korc M. Pancreatic cancer-associated stroma production . Am J Surg 2007 ; 194 : S84 - 86 . 10.1016/j.amjsurg.2007.05.004 Open DOISearch in Google Scholar

44. Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, et al. Pancancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer 2018; 6: 63. doi: 10.1186/s40425-018-0370-7 Danaher P Warren S Lu R Samayoa J Sullivan A Pekker I Pancancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) . J Immunother Cancer 2018 ; 6 : 63 . 10.1186/s40425-018-0370-7 Open DOISearch in Google Scholar

45. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014; 2: 616-31. doi: 10.1158/2326-6066.CIR-14-0027 Lutz ER Wu AA Bigelow E Sharma R Mo G Soares K Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation . Cancer Immunol Res 2014 ; 2 : 616 - 31 . 10.1158/2326-6066.CIR-14-0027 Open DOISearch in Google Scholar

46. J Gunderson A, Rajamanickam V, Bui C, Bernard B, Pucilowska J, Ballesteros-Merino C, et al. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. Oncoimmunology 2021; 10: 1900635. doi: 10.1080/2162402x.2021.1900635 J Gunderson A Rajamanickam V Bui C Bernard B Pucilowska J Ballesteros-Merino C Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer . Oncoimmunology 2021 ; 10 : 1900635 . 10.1080/2162402x.2021.1900635 Open DOISearch in Google Scholar

47. Tang R, Zhang Y, Liang C, Xu J, Meng Q, Hua J, et al. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. PeerJ 2020; 8: e9602. doi: 10.7717/peerj.9602 Tang R Zhang Y Liang C Xu J Meng Q Hua J The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma . PeerJ 2020 ; 8 : e9602 . 10.7717/peerj.9602 Open DOISearch in Google Scholar

48. Wang L, Zhang S, Li H, Xu Y, Wu Q, Shen J, et al. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma. BMC Cancer 2021; 21: 876. doi: 10.1186/s12885-021-08550-9 Wang L Zhang S Li H Xu Y Wu Q Shen J Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma . BMC Cancer 2021 ; 21 : 876 . 10.1186/s12885-021-08550-9 Open DOISearch in Google Scholar

49. Wang G, Yang L, Gao J, Mu H, Song Y, Jiang X, et al. Identification of candidate biomarker ASXL2 and its predictive value in pancreatic carcinoma. Front Oncol 2021; 11: 736694. doi: 10.3389/fonc.2021.736694 Wang G Yang L Gao J Mu H Song Y Jiang X Identification of candidate biomarker ASXL2 and its predictive value in pancreatic carcinoma . Front Oncol 2021 ; 11 : 736694 . 10.3389/fonc.2021.736694 Open DOISearch in Google Scholar

50. Lestari B, Utomo RY. CEP55 inhibitor: Extensive computational approach defining a new target of cell cycle machinery agent. Adv Pharm Bull 2022; 12: 191-99. doi: 10.34172/apb.2022.021 Lestari B Utomo RY. CEP55 inhibitor: Extensive computational approach defining a new target of cell cycle machinery agent . Adv Pharm Bull 2022 ; 12 : 191 - 99 . 10.34172/apb.2022.021 Open DOISearch in Google Scholar

51. Kalimutho M, Sinha D, Jeffery J, Nones K, Srihari S, Fernando WC, et al. CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Mol Med 2018; 10: e8566. doi: 10.15252/emmm.201708566 Kalimutho M Sinha D Jeffery J Nones K Srihari S Fernando WC CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer . EMBO Mol Med 2018 ; 10 : e8566 . 10.15252/emmm.201708566 Open DOISearch in Google Scholar

52. Sinha D, Nag P, Nanayakkara D, Duijf PHG, Burgess A, Raninga P, et al. Cep55 overexpression promotes genomic instability and tumorigenesis in mice. Commun Biol 2020; 3: 593. doi: 10.1038/s42003-020-01304-6 Sinha D Nag P Nanayakkara D Duijf PHG Burgess A Raninga P Cep55 overexpression promotes genomic instability and tumorigenesis in mice . Commun Biol 2020 ; 3 : 593 . 10.1038/s42003-020-01304-6 Open DOISearch in Google Scholar

53. Zhang X, Xu Q, Li E, Shi T, Chen H. CEP55 predicts the poor prognosis and promotes tumorigenesis in endometrial cancer by regulating the Foxo1 signaling. Mol Cell Biochem 2023; 478: 1561-71. doi: 10.1007/s11010-022-04607-w Zhang X Xu Q Li E Shi T Chen H. CEP55 predicts the poor prognosis and promotes tumorigenesis in endometrial cancer by regulating the Foxo1 signaling . Mol Cell Biochem 2023 ; 478 : 1561 - 71 . 10.1007/s11010-022-04607-w Open DOISearch in Google Scholar

54. Ye Y, Chen Z, Shen Y, Qin Y, Wang H. Development and validation of a fourlipid metabolism gene signature for diagnosis of pancreatic cancer. FEBS Open Bio 2021; 11: 3153-70. doi: 10.1002/2211-5463.13074 Ye Y Chen Z Shen Y Qin Y Wang H. Development and validation of a four-lipid metabolism gene signature for diagnosis of pancreatic cancer . FEBS Open Bio 2021 ; 11 : 3153 - 70 . 10.1002/2211-5463.13074 Open DOISearch in Google Scholar

55. Luo X, Linghu M, Zhou X, Ru Y, Huang Q, Liu D, et al. Merestinib inhibits cuproptosis by targeting NRF2 to alleviate acute liver injury. Free Radic Biol Med 2025; 229: 68-81. doi: 10.1016/j.freeradbiomed.2025.01.029 Luo X Linghu M Zhou X Ru Y Huang Q Liu D Merestinib inhibits cuproptosis by targeting NRF2 to alleviate acute liver injury . Free Radic Biol Med 2025 ; 229 : 68 - 81 . 10.1016/j.freeradbiomed.2025.01.029 Open DOISearch in Google Scholar